bluebird bio, Inc. (NASDAQ:BLUE) Position Lifted by Rhumbline Advisers

Rhumbline Advisers raised its stake in shares of bluebird bio, Inc. (NASDAQ:BLUE) by 25.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 292,436 shares of the biotechnology company’s stock after acquiring an additional 59,219 shares during the quarter. Rhumbline Advisers owned approximately 0.27% of bluebird bio worth $288,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in BLUE. BNP Paribas Financial Markets boosted its stake in bluebird bio by 144.7% during the 4th quarter. BNP Paribas Financial Markets now owns 524,963 shares of the biotechnology company’s stock valued at $724,000 after acquiring an additional 310,461 shares during the last quarter. Vestal Point Capital LP bought a new position in bluebird bio during the 4th quarter valued at $2,967,000. Ghisallo Capital Management LLC bought a new position in bluebird bio during the 4th quarter valued at $4,347,000. Pennant Investors LP bought a new position in bluebird bio during the 4th quarter valued at $121,000. Finally, Masters Capital Management LLC bought a new position in bluebird bio during the 4th quarter valued at $1,380,000. 87.43% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

BLUE has been the topic of a number of research analyst reports. Cantor Fitzgerald reiterated a “neutral” rating on shares of bluebird bio in a research note on Monday, September 16th. Wells Fargo & Company dropped their target price on shares of bluebird bio from $3.00 to $2.00 and set an “equal weight” rating on the stock in a report on Wednesday. Robert W. Baird dropped their target price on shares of bluebird bio from $7.00 to $6.00 and set an “outperform” rating on the stock in a report on Thursday, August 15th. Bank of America dropped their target price on shares of bluebird bio from $4.00 to $3.00 and set a “buy” rating on the stock in a report on Thursday, August 15th. Finally, JPMorgan Chase & Co. cut shares of bluebird bio from an “overweight” rating to a “neutral” rating in a report on Thursday, August 15th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $4.63.

bluebird bio Stock Up 1.4 %

BLUE stock opened at $0.50 on Friday. The company has a quick ratio of 0.82, a current ratio of 0.93 and a debt-to-equity ratio of 0.20. bluebird bio, Inc. has a fifty-two week low of $0.46 and a fifty-two week high of $5.53. The firm’s 50-day simple moving average is $0.77 and its 200 day simple moving average is $0.97. The stock has a market cap of $55.15 million, a PE ratio of -0.68 and a beta of 0.75.

bluebird bio Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.